Blank-check company FoxWayne Enterprises Acquisition Corp. (FOXW) is in talks to merge with Aerami Therapeutics Holdings LLC, which develops treatments for severe respiratory diseases, in a deal that’s set to value the combined entity at about $195 million, according to people with knowledge of the matter.
Update(s):
December 7, 2021: Aerami Therapeutics Holdings, a biopharmaceutical company focused on developing inhaled therapies to treat severe respiratory and chronic diseases, and FoxWayne Enterprises Acquisition (FOXW) announced they have entered into a definitive business combination agreement.